Neurogen Corp.
35 Northeast Industrial Road
Branford,
CT 06405
United States - Map
Phone: 203-488-8201
Fax: 203-481-8683
Web Site: http://www.neurogen.com
| Neurogen Corporation engages in the development of new small molecule drugs for psychiatric and neurological disorders. The companys clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of Parkinsons disease and restless legs syndrome; and MK 2295, a VR1 receptor antagonist that is in preclinical development for the treatment of pain and cough. It has a collaboration and licensing agreement with Merck Sharp & Dohme Limited to research, develop, and commercialize small molecule medicines that work by targeting the VR1 receptor; and a licensing agreement with Wyeth Pharmaceuticals to acquire worldwide rights to aplindore. The company was founded in 1987 and is based in Branford, Connecticut. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Stephen R. Davis , 48
Chief Exec. Officer, Pres, Chief Operating Officer, Director and Member of Ad Hoc Fin. Committee |
$
586.00K |
$
21.00K | Dr. Thomas A. Pitler Ph.D., 50
Chief Bus. and Financial Officer, Principal Accounting Officer and Sr. VP |
$
335.00K | N/A | Dr. Kenneth J. Sprenger M.D., M.B.B.Ch., B.Sc, 56
Sr. VP of Clinical Devel. and Operations |
$
319.00K | N/A | Mr. Jeffrey Dill Esq.,
VP Sec. and Gen. Counsel |
N/A
| N/A | Dr. Ricardo Ochoa ,
VP of Preclinical Safety |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.06% Nasdaq 
0.015 (7.36%) 
Profile
